The Xenazine Formula: Is it a Viable Model for Others?
This article was originally published in RPM Report
Despite its ultra-orphan indication, Xenazine is likely to provide a very attractive return on its development costs. It's a model that could work for other drugs-but only when several key factors work together.
You may also be interested in...
The pharmaceutical industry has long counted on patient advocates as allies in the FDA drug approval process. But their relationship on issues related to drug coverage has often been tense. The Medicare drug benefit has opened a new chapter in the relationship. Patient advocates have worked closely with the Centers for Medicare & Medicaid Services in the early months of Part D, and they have had an impact. Industry's long-time effort to establish alliances is paying off.
For now, agency appears to be in early stages of testing alternative inspection models beyond the flexibility it has been applying throughout the pandemic.
CEO accountability hearing in US House shows that the COVID-19 outbreak is helping to blunt attacks on the drug industry over its pricing – just not entirely in the way the industry hoped.